Equities

Earth Science Tech Inc

ETST:PKC

Earth Science Tech Inc

Actions
  • Price (USD)0.201
  • Today's Change0.021 / 11.67%
  • Shares traded465.16k
  • 1 Year change+567.77%
  • Beta1.7713
Data delayed at least 15 minutes, as of Jun 07 2024 20:51 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Earth Science Tech, Inc. is a holding company in the compounding pharmaceuticals and telemedicine sectors, through its wholly owned subsidiaries, RxCompoundStore.com, LLC. (RxCompound), Peaks Curative, LLC. (Peaks), and Earth Science Foundation, Inc. (ESF). RxCompound is a complete compounding pharmacy. RxCompound is licensed to fulfill prescriptions in the states of Florida, New York, New Jersey, Delaware, Pennsylvania, Rhode Island, Nevada, Colorado, and Arizona. Peaks is a telemedicine referral site focused on men’s health. Peaks orders are fulfilled by RxCompound. Patients who order Peaks via monthly subscription receive their refills automatically. Peaks is focused on men’s health, and, more specifically, ED. ESF accepts grants and donations to help those in need of assistance in paying for prescriptions.

  • Revenue in USD (TTM)5.98m
  • Net income in USD330.94k
  • Incorporated2010
  • Employees8.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
IN8BIO, Inc.0.00-31.04m60.45m31.00--3.38-----0.9154-0.91540.000.40490.00----0.00-123.61-74.18-145.63-84.42------------0.0556-------5.21---4.54--
Aeon Biopharma Inc0.00-485.01m60.64m10.00---------13.04-13.040.00-5.20------0.00-------------------27.67---------631.85------
LAVA Therapeutics NV12.54m-28.59m60.73m37.00--1.20--4.84-1.07-1.070.46681.930.107--9.09338,837.80-24.40---28.91--79.64---228.02------0.108---65.09---31.55------
Regencell Bioscience Holdings Ltd0.00-7.45m60.77m12.00--3.56-----0.5863-0.58630.001.310.00----0.00-82.73---113.11--------------0.00------21.15------
BioXcel Therapeutics Inc1.76m-153.05m61.18m74.00------34.84-5.18-5.180.0591-2.150.01340.60675.3123,729.73-116.64-74.57-151.39-84.0624.15---8,715.72-32,300.742.49-15.673.47--268.00---8.02---43.26--
AN2 Therapeutics Inc0.00-66.03m61.45m41.00--0.5554-----2.59-2.590.003.710.00----0.00-62.19---68.38--------------0.00-------51.33------
Journey Medical Corp80.00m-4.16m62.36m58.00--6.85--0.7795-0.3095-0.30954.130.64980.9852.274.281,379,276.00-5.12---17.85--66.22---5.20--0.93570.40490.5773--7.48--87.00------
RetinalGenix Technologies Inc0.00-3.73m62.51m0.00---------0.2124-0.21240.00-0.0850.00-------12,800.17-9,163.75---------------969.35--------46.58------
Champions Oncology Inc49.22m-9.73m62.74m230.00------1.27-0.7183-0.71833.64-0.15141.56--6.17214,017.40-30.91-5.40-96.45-11.8840.0947.96-19.76-3.09--------9.6921.63-1,073.54--18.50--
Earth Science Tech Inc5.98m330.94k62.94m8.00208.2329.16118.9210.520.0010.0010.01950.00693.1611.41106.07747,970.0017.50-224.8442.70--62.2937.795.53-333.580.386-0.38990.1023--243.77-36.31-111.95------
enVVeno Medical Corp0.00-22.12m63.32m31.00--1.49-----1.70-1.700.003.180.00----0.00-54.31-58.43-56.14-62.76-------260,799.30----0.00------4.67--21.58--
CNS Pharmaceuticals Inc0.00-17.46m63.88m3.00---------179.17-179.170.00-20.760.00----0.00-384.86-132.47---185.75---------------------23.42------
Bioqual Inc62.86m957.02k64.85m108.0067.761.6718.491.031.071.0770.2843.411.04--2.99--1.598.141.809.5214.1319.361.527.13----0.0021.43-5.2711.79-84.12-25.261.6010.76
China Health Industries Holdings, Inc.117.28k-1.51m64.88m32.00------553.19-0.023-0.0230.0018-0.03490.00440.569225.253,665.00-5.723.04-7.603.66-2.3769.55-1,287.1328.610.0377--1.68--41,225.93-55.72-15.49------
Avrobio Inc0.0030.31m65.01m13.002.100.73152.12--0.69030.69030.001.980.00----0.0034.57-45.2238.47-49.14------------0.00------111.48---66.27--
Lantern Pharma Inc0.00-17.53m65.74m21.00--1.84-----1.62-1.620.003.320.00----0.00-36.82-28.83-39.63-30.17------------0.00-------11.93------
Data as of Jun 07 2024. Currency figures normalised to Earth Science Tech Inc's reporting currency: US Dollar USD

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
SKY Investment Group LLCas of 31 Mar 20240.000.00%
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.